Health
Healthcare
2014 IPO

Diplomat Pharmacy

$5.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-2.85%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell DPLO and other stocks, options, ETFs, and crypto commission-free!

About

Diplomat Pharmacy, Inc. engages in the provision of specialty pharmacy and infusion services. It operates through the Specialty and Pharmacy Benefit Management segments. Read More The Specialty segment offers a range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost specialty drugs, and a wide range of applications. The Pharmacy Benefit Management segment provides services designed to help the customers reduce the cost and manage the complexity of their prescription drug programs. The company was founded by Dale Hagerman and Philip Hagerman in 1975 and is headquartered in Flint, MI.

Employees
2,335
Headquarters
Flint, Michigan
Founded
1975
Market Cap
392.99M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.09M
High Today
$5.23
Low Today
$4.97
Open Price
$5.19
Volume
235.26K
52 Week High
$28.74
52 Week Low
$4.97

Collections

Health
Healthcare
2014 IPO
US
North America

News

TradingNewsNowMay 9

Current Trend: Diplomat Pharmacy (NYSE: DPLO)

Diplomat Pharmacy is in the healthcare sector and is in the drug manufacturers industry. The company CEO is Brian T. Griffin. Diplomat Pharmacy Inc is a provider of pharmaceutical drugs in the United States. It generates its revenue through the sale of prescriptions drugs for serious diseases such as hepatitis and multiple sclerosis. Previous Intraday Trading Performance: The DPLO stock showed a previous change of 2.79% with an open at 5.67 and a close of 5.90. It reached an intraday high of 6.06 and a lo...

143
Seeking AlphaMay 7

Diplomat Pharmacy, Inc. (DPLO) CEO Brian Griffin on Q1 2019 Results - Earnings Call Transcript

Diplomat Pharmacy, Inc. (NYSE:DPLO) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Terri Anne Powers - Vice President, Investor Relations Brian Griffin - Chairman & Chief Executive Officer Dan Davison - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Steven Valiquette - Barclays A.J. Rice - Crédit Suisse Jon Kaufman - William Blair David Larsen - Leerink Eric Coldwell - Baird Ricky Goldwasser - Morgan Stanley Charles Rhyee - Cowen John Ra...

85
Yahoo FinanceMay 7

Diplomat Pharmaceuticals (DPLO) Reports Q1 Loss, Tops Revenue Estimates

Diplomat Pharmaceuticals (DPLO) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.20 per share a year ago.

43

Earnings

-$0.19
-$0.04
$0.10
$0.25
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.